This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity
dalia A gomaa | |
01063410525 | |
[email protected] |
5 Years - 18 Years
Phase 3
Interventional
All
Drug
children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity
age 5-18 years
Another chronic hemolytic anemia.
Patients with documented causes of pulmonary hypertension other than SCD.
Allergy to L-arginine.
Patients with Asthma.
Hepatic dysfunction: serum Alanine Aminotransferase (ALT) > 3X upper value.
Renal dysfunction: Creatinine level greater than or equal to 1.2 mg/dl.